Promising combo for tough leukemia stalls: trial ends early
NCT ID NCT05464836
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested two drugs, CB-103 and venetoclax, in adolescents and young adults with T-cell acute lymphoblastic leukemia (T-ALL) that had come back or not responded to treatment. The goal was to see if the combination could control the disease. However, the study was terminated early after enrolling only 2 participants, so results are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CB-103 and venetoclax
What this could lead to
If this combination works, it could offer a new treatment option for young patients with hard-to-treat T-cell leukemia.
What could go wrong
The trial was terminated early with only 2 participants, so we have very little data. It is unclear if the combination is safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States